acetylleucine

{{Short description|Compound}}

{{Use dmy dates|date=September 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{chembox

| ImageFile = Acetylleucine.svg

| ImageFile_Ref = {{chemboximage|correct|??}}

| ImageSize = 160

| ImageName = Stereo, skeletal model of acetylleucine (S)

| ImageCaption = (S)-(−)-N-Acetyl-leucine

| IUPACName = 2-Acetamido-4-methylpentanoic acid{{cite web | title = N-Acetyl-DL-leucine | website = PubChem Open Chemistry Database | url = https://pubchem.ncbi.nlm.nih.gov/compound/N-Acetyl-DL-leucine#section=Top | access-date = 26 Mar 2017}}

| OtherNames = N-Acetylleucine; N-Acetyl-L-Leucine

|Section1={{Chembox Identifiers

| index_label = Racemic

| index1_label = S (−)

| index2_label = R (+)

| CASNo = 99-15-0

| CASNo_Ref = {{cascite|correct|CAS}}

| CASNo1 = 1188-21-2

| CASNo1_Ref = {{cascite|correct|CAS}}

| CASNo2 = 19764-30-8

| CASNo2_Ref = {{cascite|correct|CAS}}

| PubChem = 1995

| PubChem1 = 70912

| PubChem2 = 1241420

| ChemSpiderID = 1918

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID1 = 64075

| ChemSpiderID1_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID2 = 1042393

| ChemSpiderID2_Ref = {{chemspidercite|correct|chemspider}}

| UNII = K76S41V71X

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII1_Ref = {{fdacite|correct|FDA}}

| UNII1 = E915HL7K2O

| UNII2_Ref = {{fdacite|correct|FDA}}

| UNII2 = 91WU82GA22

| EINECS = 202-734-9

| KEGG = D07350

| KEGG_Ref = {{keggcite|correct|kegg}}

| MeSHName = acetylleucine

| ChEBI = 17786

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 174357

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL1 = 56021

| ChEMBL1_Ref = {{ebicite|correct|EBI}}

| Beilstein = 1724849 (S)-(−)

| Gmelin = 985259 (S)-(−)

| 3DMet = B00487

| SMILES = CC(C)CC(NC(C)=O)C(O)=O

| StdInChI = 1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = WXNXCEHXYPACJF-UHFFFAOYSA-N

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

}}

|Section2={{Chembox Properties

| C=8 | H=15 | N=1 | O=3

| Appearance = White crystals

| MeltingPtK = 158 to 160

| LogP = −0.265

| pKa = 3.666

| pKb = 10.331

}}

|Section8={{Chembox Related

| OtherCompounds = ENU

}}

| Section6 = {{Chembox Pharmacology

| Pharmacology_ref =

| ATCCode_prefix = N07

| ATCCode_suffix = CA04

| ATC_Supplemental =

| ATCvet =

| Licence_EU =

| INN =

| INN_EMA =

| Licence_US =

| Legal_status =

| Legal_AU =

| Legal_AU_comment =

| Legal_CA =

| Legal_CA_comment =

| Legal_NZ =

| Legal_NZ_comment =

| Legal_UK =

| Legal_UK_comment =

| Legal_US =

| Legal_US_comment =

| Legal_EU =

| Legal_EU_comment =

| Legal_UN =

| Legal_UN_comment =

| Pregnancy_category =

| Pregnancy_AU =

| Pregnancy_AU_comment =

| Dependence_liability =

| AdminRoutes =

| Bioavail =

| ProteinBound =

| Metabolism =

| Metabolites =

| OnsetOfAction =

| HalfLife =

| DurationOfAction =

| Excretion =

}}

}}

Acetylleucine (N-acetyl-leucine) is a modified leucine amino acid.

Two forms are commercialized: N-acetyl-DL-leucine (sold under the brand Tanganil, among others, and used in the treatment of vertigo{{cite web |date=19 Dec 2016 |title=N07CA04 (acetylleucine) |url=https://www.whocc.no/atc_ddd_index/?code=N07CA04&showdescription=yes |access-date=26 Mar 2017 |website=WHO Collaborating Centre for Drug Statistics Methodology |publisher=Norwegian Institute of Public Health}}) and N-acetyl-L-leucine (levacetylleucine, sold under the brand name Aqneursa, and used for the treatment of neurological manifestations of Niemann-Pick disease type C).{{Cite journal |last1=Oertel |first1=Wolfgang H. |last2=Janzen |first2=Annette |last3=Henrich |first3=Martin T. |last4=Geibl |first4=Fanni F. |last5=Sittig |first5=Elisabeth |last6=Meles |first6=Sanne K. |last7=Carli |first7=Giulia |last8=Leenders |first8=Klaus |last9=Booij |first9=Jan |last10=Surmeier |first10=D. James |last11=Timmermann |first11=Lars |last12=Strupp |first12=Michael |date=2024-09-02 |title=Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern—case reports |journal=Nature Communications |volume=15 |issue=1 |pages=7619 |doi=10.1038/s41467-024-51502-7 |issn=2041-1723 |pmc=11369233 |pmid=39223119|bibcode=2024NatCo..15.7619O }}